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The management of patients with significant in-stent restenosis (ISR) with drug-eluting
stent is still not well defined. Various treatment modalities include plain old balloon an-
gioplasty (POBA), metallic stent, cutting or scoring balloon and drug-eluting balloon (DEB).
Bioresorbable vascular scaffold (BVS) is the latest technology for the treatment of de novo
coronary artery lesions. The use of BVS in ISR is based on the rationale of local drug de-
livery as achieved by DEB without the permanent bi-layer of metal and also stabilizes
dissection flaps and prevents acute recoil as provided by metallic stent. To the best of our
knowledge this is the first case report of the use of BVS in patient with ISR.
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
The percutaneous coronary intervention (PCI) for treatment of
de novo coronary artery disease is well established but the
treatment of in-stent restenosis (ISR) in patients with drug-
eluting stent (DES) is still a major clinical challenge. Various
treatment modalities have been used for treatment of ISR
ranging from plain old balloon angioplasty (POBA), metallic
stent, cutting or scoring balloon to drug-eluting balloon (DEB).
Here,wereportacaseofDES-ISRtreatedbyusingaBioresorbable
Vascular Scaffold (BVS) in patient with unstable angina.2. Case report
A 40-year-old hypertensive and non-diabetic female was
admitted to our departmentwith gradually progressive angina7; fax: þ91 79 26842288.
Deora).
ociety of India. All rightsfor last 6 months. She had significant past history of anterior
wall myocardial infarction two years prior to admission and
underwent PCI to left anterior descending coronary artery
(LAD) with sirolimus eluting stent through right transradial
approach.12-lead electrocardiogram revealed Q waves with
inverted T waves in anterior precordial leads suggesting
old anterior wall myocardial infarction. Two-dimensional
cross-sectional echocardiographic and Doppler examination
revealed severe left ventricle systolic dysfunction (LVEF~ 30%).
In view of crescendo symptoms, after informed consent, cor-
onary angiography was performed via left transradial access
using6Fhydrophilic introducersheathand5FTIG4.0catheter,
which revealed significant ISR in proximal segment of LAD
(Panel A, B Fig. 1; S Video 1). Left circumflex coronary (LCX) and
right coronary artery (RCA) were non obstructive. PCI of LAD
was planned and left coronary ostium was engaged with 6F
EBU guide catheter (Launcher, Medtronic, Inc., Minneapolis,
MN). The lesion was crossed with 0.009-inch rotawire andreserved.
Fig. 1 e Left coronary angiogram in RAO caudal (Panel A) and AP cranial view showing significant ISR in proximal LAD
(Arrow, Panel B). AP caudal view showing rotablation with 1.5 mm burr (Arrow, Panel C) and predilation with PTCA balloon
dilatation catheter (Arrow, Panel D) (RAO, Right anterior oblique; AP, Anterioeposterior; ISR, In-stent restenosis; LAD, left
anterior descending artery; PTCA, Percutaneous transluminal coronary angioplasty).
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 4 5 9e4 6 1460rotablation was performed using a 1.5-mm rotaburr (Boston
Scientific, Boston, MA, USA) at 1,50,000 rpm (Arrow, Panel C
Fig. 1; S Video 2). After rotablation, the lesionwas crossedwith
0.014-inch BMW guidewire (Abbott Vascular, Santa Clara, CA)
and rotawire was removed. The lesion was pre-dilated with
2  10 mmMaverick PTCA balloon dilatation catheter (Boston
Scientific, Boston,MA, USA) (Arrow, Panel D Fig. 1) afterwhich,
a 3.5mm 28mmAbsorb™BVS (Abbott Vascular, Santa Clara,
CA) was deployed with the help of two platinum markers at
10 atmwith goodangiographic result (Arrow, PanelA, B Fig. 2; S
Video 3). Patient remainedhemodynamically stable during the
procedure and was asymptomatic at 1-month follow up.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.ihj.2014.05.016.3. Discussion
The management of patients with ISR is still a major clinical
challenge even in era of DES. Although the incidence of ISR issignificantly reduced with the use of DES as compared to bare
metal stent (BMS) but the absolute number of cases is
increased with increase in the complex and multivessel PCI.
Moreover, because of diverse etiology of DES-ISR the optimal
treatment modality is difficult to determine.1 The treatment
option varies from using vascular brachytherapy (VBT), larger
high-pressure balloon dilatation, same or different DES, cut-
ting or scoring balloon and drug-eluting balloon (DEB) but still
the optimum treatment strategy is undefined. The VBT is not
used now-a-days because of better alternative options and
radiation source related logistic issues.2 The plain old balloon
angioplasty (POBA) is mainly limited by frequent slippage of
the balloon during inflation and high rate of recurrent reste-
nosis as compared to DES.3,4 This problem is overcome by
using cutting or scoring balloon but has limitation because of
its larger profile which makes it difficult to cross the stented
segments especially when the ISR is diffuse. Even in focal ISR,
DES is better than cutting balloon in terms of preventing late
luminal loss and in preventing recurrent restenosis.5 Out-
comes of same drug DES implantation in focal DES-ISR are
excellent although in patientswith diffuse DES-ISR, a different
Fig. 2 e BVS platinummarkers representing the edges of the scaffold are seen placed across the lesion in RAO caudal (Arrow,
Panel A) and AP cranial view (Arrow, Panel B) confirming the proper position of the scaffold (BVS, Bioresorbable scaffold;
RAO, Right anterior oblique; AP, Anterioeposterior).
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backs of treatment of ISR with implantation of a stent inside a
stent is the metal burden in that segment of the vessel. In
large caliber coronary arteries, this strategy is fairly well
tolerated, although in smaller caliber vessels where ISR is
more likely to occur, metal burden is a limiting issue. DEB is a
novel technique of local drug delivery without adding second
layer of metal and hence has theoretical advantage over DES
but is limited by failure to provide the mechanical scaffolding
support to combat acute recoil and to cover dissection flaps.7
BVS is the latest advance in the armamentarium of interven-
tional therapies for treating de novo significant coronary ar-
tery disease. Recent data from trials have suggested many
advantages of BVS over DES.8 The rationale of using BVS in
DES-ISR is based on the concept of repeat local drug delivery
as achieved by DEB with the benefits of a scaffold to stabilize
dissection flaps, and prevent acute recoil as provided by
metallic stent, without the permanent bi-layer of metal, that
in some vessels, may in and by itself create flow abnormality.94. Conclusion
This case is the first human experience demonstrating feasi-
bility, and acute efficacy of BVS in a patient with DES-ISR. In
view of its appealing biologic advantage, the efficacy and out-
comes of a BVSbased treatment strategy forDES-ISRneed to be
evaluated in comparison to other established PCI based thera-
pies, suchas repeatDES implantation, in a randomized setting.Conflicts of interest
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